SELLAS Life Sciences reaches 80th event in Phase 3 REGAL leukemia trial

SELLAS Life Sciences says its Phase 3 REGAL trial of galinpepimut-S in acute myeloid leukemia has reached its 80th event. Coverage on Yahoo Finance, TradingView and Seeking Alpha followed, with one Seeking Alpha analysis questioning the trial's odds.

Timeline

1. 28 Oct, 13:10 UTCFirst appeared on Google Trends
2. 28 Oct, 13:10 UTCYahoo Finance covers 80th event announcement

Top sources

• sls stockGoogle Trends
• Sellas Life Sciences: The Longer The Wait, The More Likely A REGAL Failure (NASDAQ:SLS)Seeking Alpha
• Sellas Life Sciences Reaches 80Th Event In Phase 3 Regal Trial Of Galinpepimut-S (Gps) In Acute Myeloid LeukemiaTradingView